Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) logo

Product menu

NA

Trelegy Ellipta for COPD

Access clinical evidence, real-world data and COPD guidelines to support treatment decisions with Trelegy Ellipta in appropriate adult patients.

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).1

Access clinical evidence and practical guidance for appropriate patients

Illustration of lungs and paperwork symbolising guidelines for COPD, with the letters GSK in the pages

Understanding COPD & guidelines

Find out more about NICE & GOLD guidelines for COPD maintenance therapy and exacerbations, including LAMA/ LABA and ICS/LAMA/LABA recommendations

Learn
Illustration of a Trelegy Ellipta outline with a pair of lungs inside.

Explore Trelegy Ellipta Studies

Real-world evidence for Trelegy Ellipta versus other triple therapy

Explore
Illustration of the outline of a Trelegy Ellipta with a pair of lungs inside, with other inhalers nearby

Trelegy Ellipta in practice

Learn about the Ellipta device in practice including ease of use, time to teach and inspiratory flow

Find
Illustration of a pair of lungs

Trelegy Ellipta Events & Support

Patient resources and events

Access

Video: Professor Richard Russell

Explore the challenges faced by patients with COPD

Image of GSK summary of NICE and GOLD COPD Guidelines

COPD Guidelines

GSK summary of where triple therapy fits into the NICE and GOLD guidelines

Access
Image showing Inhale, a hub to support COPD consultations

Inhale hub for consultation support

Information to support COPD consultations with your patients and support day-to-day management after a decision to prescribe Trelegy Ellipta has been made.

Explore
Image of Beverley Bostock

Case Study: COPD Management in Practice

See how Beverley Bostock approaches COPD care to support improved patient outcomes.

Find insights

In the UK, there is 1 exacerbation every 20 seconds2

Explore the interventions that can positively impact outcomes with Professor Richard Russell

Find out more

Resources for COPD management

Image of the Trelegy Ellipta

CLINICAL DATA

Comparative Study overview

Real-world evidence for Trelegy Ellipta

View resource
Image of Ellipta inhalation trainer

GUIDELINES

Try the Ellipta

Order inhalation trainers for your patients with COPD to test their ability to use the Ellipta inhaler

View resource
Shopping trolley icon

PATIENT SUPPORT

Online ordering

Explore our online catalogue of resources to support patients with COPD who have been prescribed Trelegy Ellipta

View resource

Abbreviations:

BUD: budesonide; FOR: formoterol; GOLD: Global Initiative for Chronic Obstructive Lung Disease; GLY: glycopyrronium; ICS: inhaled corticosteroid; LABA: long-acting beta agonist; LAMA: long-acting muscarinic antagonist; NICE: National Institute for Health and Care Excellence

References:

  1. Trelegy Ellipta Summary of Product Characteristics.
  2. COPD Voices. A matter of life and breath. 2025. Available at: www.kcl.ac.uk/sims/assets/copd-voices-final-29042025.pdf

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.

September 2026 | PM-GB-FVU-WCNT-260004 (V1.0)